Adocia SA · EURONEXT:ADOC

Adocia SA — Investor Presentation (April 2022)

38 slides from Adocia SA's investor presentation, April 2022

  1. Slide 1: Corporate Presentation April 2022

    Slide 1: Corporate Presentation April 2022

    Corporate Presentation April 2022

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This corporate presentation (the “Presentation”) has The Presentation does not purport to contain well as the trends in the sector in which the Group been prepared by ADOCIA S.A. (the “Company” and, comprehensive or complete information about the operates, may differ materially from those

  3. Slide 3: Highly experienced management team

    Slide 3: Highly experienced management team

    Highly experienced management team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager, President & CEO R&D Director Chief Financial Officer Co-founder Co-founder Jérémy Benattar Michael PharmD, Eng Nguyen Director of Marketing & Head of BD,US Strategy • Co-founde

  4. Slide 4: Executive Summary

    Slide 4: Executive Summary

    Executive Summary Our mission: Discovery and development of therapeutic solutions in the 1 field of metabolic diseases, primarily diabetes and obesity Business model: Licensing to pharma partners after proof-of-concept 2 • Proprietary specialty products based on approved drug • Proprietary technolog

  5. Slide 5: Adocia's partnering models: strategic pillars to ensure cash income sustainability

    Slide 5: Adocia's partnering models: strategic pillars to ensure cash income sustainability

    Adocia’s partnering models: 2 strategic pillars to ensure cash income sustainability Licensing Technological platforms Licensing Proprietary specialty products applied to pharma partner’s based on approved drugs proprietary products • $50m upfront • BioChaperone LisproPartnered • $85m upcoming devel

  6. Slide 6: Proprietary technological platforms with strong IP strategy

    Slide 6: Proprietary technological platforms with strong IP strategy

    Both Adocia’s partnering models are based on proprietary technological platforms with strong IP strategy BioChaperone® AdOral ® AdoShell ® • Pharmaceutical excipient • Pharmaceutical excipient • Hydrogel scaffold • Forms a complex with therapeutic • Enhances proteins/peptides oral route • Encapsulat

  7. Slide 7: Proprietary specialty products based on approved drugs

    Slide 7: Proprietary specialty products based on approved drugs

    Proprietary specialty products based on approved drugs 7

  8. Slide 8: Diabetes and Obesity: worldwide chronic pandemics

    Slide 8: Diabetes and Obesity: worldwide chronic pandemics

    Diabetes and Obesity: worldwide chronic pandemics 537 million people live with diabetes1 Diabetes is closely linked to obesity 1 in 11 • In the US, 65% of adults with type 13 diabetes and 85% of type 24 are overweight or obese • Several hormones are involved in both diabetes and obesity 1.9 billion

  9. Slide 9: Adocia's vision of metabolic diseases treatment: from hormonal to cell therapies

    Slide 9: Adocia's vision of metabolic diseases treatment: from hormonal to cell therapies

    Adocia’s vision of metabolic diseases treatment: from hormonal to cell therapies Immuno-protective scaffold for islets of Langerhans Oral Delivery of hormones Pluri-hormonal formulations Improved proteins/peptides formulations Adocia is taking on high challenges, that require innovative mindset and

  10. Slide 10: A rich specialty product pipeline to maximize chances of success

    Slide 10: A rich specialty product pipeline to maximize chances of success

    A rich specialty product pipeline to maximize chances of success Preclinic Phase 1 Phase 2 Phase 3 Upcoming milestones BC Lispro Phase 3 in China expected in 2022 Ultra-Rapid Insulin Partnered U100 / U200 Phase 3 in USA and Europe expected in 2022* Insulins Combination BC Combo U200 Partnered Phase

  11. Slide 11: BioChaperone Lispro

    Slide 11: BioChaperone Lispro

    BioChaperone® Lispro The next best-in-class Rapid Acting Insulin for a tighter glycemic control Corporate Presentation 11

  12. Slide 12: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class

    Slide 12: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class

    BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster- out”) vs. comparators AUC0-2h: -61%* • Good tolerance for optimized daily use • Range of strengths (U100

  13. Slide 13: BC Lispro is ready to start phase 3 pivotal program

    Slide 13: BC Lispro is ready to start phase 3 pivotal program

    BC Lispro is ready to start phase 3 pivotal program • Only 3 ultra-rapid insulins will compete in the $9bn1 prandial insulin market, addressing the needs of 34 millions mealtime insulins users (T1D + T2D): BC Lispro • Licensed to Tonghua Dongbao (THDB) for development & commercialization for Chinese

  14. Slide 14: BC Combo, glargine-lispro premix

    Slide 14: BC Combo, glargine-lispro premix

    BC Combo, glargine-lispro premix The best insulin premix Corporate Presentation 14

  15. Slide 15: BC Combo, a unique combination of glargine and lispro

    Slide 15: BC Combo, a unique combination of glargine and lispro

    BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins BioChaperone® Combo 1 product Once or twice a day U200 fixed ratio (150 U/mL glargine - 50 U/mL lispro) Less hyperglycemia  Simple  Affordable Less hypoglycemia  Limited number of injections 

  16. Slide 16: BC Combo is licensed to Tonghua Dongbao in China

    Slide 16: BC Combo is licensed to Tonghua Dongbao in China

    BC Combo is licensed to Tonghua Dongbao in China Premix market Tonghua Dongbao deal $2,7bn1 Western Markets: T2D patients • $40m upfront $2,3bn1 • $50m upcoming development Emerging Markets: milestones T1D & T2D ~65% • Double-digit royalties on sales patients Market share in India and China (volume)

  17. Slide 17: Insulin & Amylin analogs combinations M1Pram and BC LisPram

    Slide 17: Insulin & Amylin analogs combinations M1Pram and BC LisPram

    Insulin & Amylin analogs combinations M1Pram and BC LisPram First-in-class combination products, the 5th generation of prandial insulin 17

  18. Slide 18: Amylin hormone is missing in people with diabetes

    Slide 18: Amylin hormone is missing in people with diabetes

    Amylin hormone is missing in people with diabetes, and it contributes to diabetes dysregulations Meal Pancreas Insulin Normal pattern Level of secretion (relative scale) Amylin Insulin Glucagon Secreted 0 1 2 3 4 5 6 Co-secreted Glucagon by α-cells Time (hours) by β-cells Meal Level of secretion Glu

  19. Slide 19: Pramlintide (Symlin), an amylin analog, has demonstrated clinical benefits

    Slide 19: Pramlintide (Symlin), an amylin analog, has demonstrated clinical benefits

    Pramlintide (Symlin®), an amylin analog, has demonstrated its clinical benefits when associated with insulin and is FDA approved in T1D and T2D Pramlintide pharmacological effects Symlin limitations 1. Activates amylin receptors in different brain areas 1. 3 additional daily injections required on t

  20. Slide 20: Adocia targets to replace insulin by bi-hormonal insulin therapies

    Slide 20: Adocia targets to replace insulin by bi-hormonal insulin therapies

    Adocia targets to replace insulin by bi-hormonal insulin therapies Medical Multi-hormonal Insulin/Pramlintide is the first prandial benefits combinations insulin able to improve: M1Pram, BC LisPram  HbA1c  Time-in-Range Ultra-Rapid Insulins  Weight loss BC Lispro, Fiasp®, Lyumjev®  Well-being Ra

  21. Slide 21: One formulation for pen and one for pump

    Slide 21: One formulation for pen and one for pump

    Adocia is developing one formulation for pen and one for pump Type Pré-clinique Phase I Phase II Phase III Upcoming Regular insulin Pramlintide Clinical Q2 2022 M1Pram POC Ph2 in T1D results in Pen (MDI) communication Rapid insulin Pramlintide Q3 2022 BC LisPram Ph1 T1D pump study results in Pump MD

  22. Slide 22: Promising Phase 1b results of M1Pram in pen vs Novolog

    Slide 22: Promising Phase 1b results of M1Pram in pen vs Novolog

    Promising Phase 1b results of M1Pram in pen vs Novolog Results of phase 1b part B: 3-week outpatient trial - M1Pram vs. Novolog (n=16; High dose of insulin) Average glycemia Weight Time In Range After 3 weeks only: 164 16,2 0,5 162 0.4 16  Better post-prandial 0 15,8 glycemic control 160 -7 mg/dL 1

  23. Slide 23: M1Pram in pen generates high expectations from KOLs

    Slide 23: M1Pram in pen generates high expectations from KOLs

    M1Pram in pen generates high expectations from KOLs ”By mimicking the normal co-secretion of amylin and “This combination has the potential to insulin with meals, this 2-in-1 combination has the finally deliver on the promise of pramlintide potential to address the persisting unmet need for for a la

  24. Slide 24: BC LisPram: the optimal combination for pumps

    Slide 24: BC LisPram: the optimal combination for pumps

    BC LisPram: the optimal combination for pumps Clinical Proof-of-Concept established at Mc Gill University, Canada, Adocia intends to reproduce A. Haidar POC with its fixed by Dr. Ahmad Haidar combination of Lispro and Pram delivered in one single pump Lispro in one pump vs. Lispro and Pramlintide ad

  25. Slide 25: Immuno-protective scaffold for islets of Langerhans graft for diabetes

    Slide 25: Immuno-protective scaffold for islets of Langerhans graft for diabetes

    Immuno-protective scaffold for islets of Langerhans graft for diabetes Improving pancreatic islets transplant techniques 25

  26. Slide 26: Immuno-protective hydrogel scaffold to protect pancreatic islets transplants

    Slide 26: Immuno-protective hydrogel scaffold to protect pancreatic islets transplants

    Adocia developed an immuno-protective hydrogel scaffold to protect pancreatic islets transplants Adocia Hydrogel scaffold Transplant Organoid External Islets sourcing (Allogenic/stem-cell) Adocia’s goal is to develop islets transplantation without immunosuppressive treatments 26

  27. Slide 27: Immuno-protective Hydrogel scaffold for islets transplants

    Slide 27: Immuno-protective Hydrogel scaffold for islets transplants

    Adocia’s immuno-protective Hydrogel scaffold for islets transplants Semipermeable Hydrogel scaffold Islets Allogenic / stem-cell Glucose, oxygen, nutrients… Macrophages Insulin Antibodies Tomorrow, this technology could be applied to any type of stem cells 27

  28. Slide 28: Development achievements

    Slide 28: Development achievements

    Development achievements Insulin secretion Encapsulated Islets In vitro encapsulation results in response to glucose Naked Islets  Simple and cell-friendly process 3G 15G 3G  Human islets viable and functional 6  Fast insulin delivery to glucose stimuli Normalized insulin secretion 5 4 In vivo gr

  29. Slide 29: Obesity: personalized multi-hormonal treatment

    Slide 29: Obesity: personalized multi-hormonal treatment

    Obesity Personalized multi-hormonal obesity treatment: a new paradigm “At Adocia, we believe that long lasting victory against obesity will come from the patients – so let’s give them the tools they need” 29

  30. Slide 30: Combinations of diabetes hormones to treat obesity

    Slide 30: Combinations of diabetes hormones to treat obesity

    Combinations of “diabetes” hormones appears to be a revolutionary way to treat obesity Product Class Mean Mean Weight Loss Weight Loss expected Targeted (standalone) (combo) AMYLIN PramExe Amylin analog -7,9%1 -15% Pramlintide Exenatide GLP1-RA - 8%2 Diabetes GLP-1 Obesity BC GluExe Glucagon -7 to -

  31. Slide 31: Biochaperone Glucagon Exenatide (BC GluExe)

    Slide 31: Biochaperone Glucagon Exenatide (BC GluExe)

    Biochaperone® Glucagon Exenatide (BC GluExe) Proof-of-Concept established in obese mice 120 110 100 Saline (vehicle) BC Exenatide* Exenatide “standalone” showed a significant 90 -10% Exenatide -10% weight loss compared to vehicle BW (%) 80 70 -25% BC Glucagon Exenatide*** showed a significant -25% w

  32. Slide 32: Adocia is developing patient-centric treatments

    Slide 32: Adocia is developing patient-centric treatments

    Adocia is developing patient-centric treatments CURRENT PARADIGM ADOCIA’S PARADIGM Long acting GLP-1 RA are being developed to limit the The patient wears a patch-pump number of injections to deliver combinations of short acting hormones However, despite demonstrated efficacy, GLP-1 RA class goes al

  33. Slide 33: Personalize patient experience by offering dose flexibility

    Slide 33: Personalize patient experience by offering dose flexibility

    Adocia’s innovation is to personalize patient experience by offering dose flexibility n days infusion n days infusion 1 day off Concentration 4x Patient can: • Intensify the treatment by increasing Concentration 2x the dosage to obtain maximum results Concentration 1x • Stop temporarily by switching

  34. Slide 34: Financial & news flow

    Slide 34: Financial & news flow

    Financial & news flow ADOCIA f-

  35. Slide 35: News flow

    Slide 35: News flow

    News flow BC Lispro M1Pram Hormonal combinations in obesity • In China (with partner THDB): • Phase 2 study in T1D in MDI • FIH study 2022/2023 Phase 3 start expected in 2022 (Multiple Daily Injection) completed • In USA/EU: Phase 3 launch scheduled in 2022 • Results communication in Cell Therapy Q2

  36. Slide 36: Key financials & shareholder information

    Slide 36: Key financials & shareholder information

    Key financials & shareholder information Key financials features1 Shareholder ownership Market information Already received • Listed on Euronext Paris (ADOC) • €85m raised since inception • 7.4m shares outstanding • $120m received from partnership Soula Family • ADR program in the US (ADOCY) 22,0% E

  37. Slide 37: Summary

    Slide 37: Summary

    Summary • Adocia’s projects are based on 3 proprietary technologies: BioChaperone®, AdOral®, AdoShell® • A well-advanced and diversified pipeline with products ready-to-license: • 5 products with clinical proof-of-concept based on its proprietary BioChaperone® platform o BC Lispro is planned to ente

  38. Slide 38: Thank you for your kind interest

    Slide 38: Thank you for your kind interest

    Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com

Source: Internet Archive copy of adocia.com

More decks from Adocia SA

All 49 Adocia SA decks